SN instructed patient and caregiver that Apixaban ( Eliquis ) is a anticoagulant for the treatment of venous thromboembolic events. It is indicated for the following: to lower the risk of stroke and embolism in patients with nonvalvular atrial fibrillation, deep vein thrombosis ( DVT ) prophylaxis. DVT's may lead to pulmonary embolism ( PE ) in knee or hip replacement surgery patients, treatment of both DVT and PE, to reduce the risk of recurrent DVT and PE after initial therapy. Apixaban can increase the risk of bleeding and may cause serious, potentially fatal, bleeding. Concurrent use with drugs affecting hemostasis ( e.g. other anticoagulants, heparin, aspirin and other antiplatelet drugs, selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, and non steroidal anti-inflammatory drugs ( NSAIDs ) can further increase the risk of bleeding.